Overview

A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

Status:
Completed
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) and oral isavuconazonium sulfate administered daily in pediatric patients. The PK data will be utilized to establish a pediatric population PK model of isavuconazole, the active moiety of isavuconazonium sulfate.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborator:
Basilea Pharmaceutica International Ltd
Treatments:
Isavuconazole